Verition Fund Management
PLX icon

Verition Fund Management’s Protalix BioTherapeutics PLX Stock Holding History

Verition Fund Management’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-23,465
Closed -$29.6K – 3203
2024
Q1 		$29.6K Buy
+23,465
New +$35K ﹤0.01% 2663
2023
Q3 		– Sell
-54,474
Closed -$109K – 2608
2023
Q2 		$109K Buy
+54,474
New +$130K ﹤0.01% 1965

Other funds holding PLX

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Verition Fund Management's PLX Position: Q2 2024 in Review

Verition Fund Management sold out of Protalix BioTherapeutics (PLX) in Q2 2024, closing a stake of 23,465 shares — an estimated $29.6K sold.

Verition Fund Management first reported a position in PLX in Q2 2023 and held it in 2 quarters. The position peaked at $109K in Q2 2023. 66 funds tracked by Wall St. Rank hold PLX as of Q2 2024.

  • Verition Fund Management reported no remaining Protalix BioTherapeutics position as of Q2 2024 after selling out during the quarter.
  • Verition Fund Management sold 23,465 Protalix BioTherapeutics shares in Q2 2024, an estimated $29.6K.
  • Verition Fund Management first reported a position in Protalix BioTherapeutics in Q2 2023 and held it in 2 quarters.
  • Verition Fund Management's Protalix BioTherapeutics position peaked at $109K in Q2 2023.
  • 66 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2024.

Based on Verition Fund Management's 13F filing for Q2 2024, filed 14 Aug 2024.